计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| L172696-5mg |
5mg |
现货 ![]() |
| |
| L172696-10mg |
10mg |
现货 ![]() |
| |
| L172696-25mg |
25mg |
现货 ![]() |
| |
| L172696-50mg |
50mg |
现货 ![]() |
| |
| L172696-100mg |
100mg |
现货 ![]() |
|
| 英文别名 | NYNZQNWKBKUAII-KBXCAEBGSA-N | DB14723 | Q27081513 | ARRY470 | ARRY-470 | ARRY-470; larotrectinib | AS-35231 | Larotrectinib [INN] | larotrectinibum | Vitrakvi | 1223403-58-4 | (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin -1-yl)pyrazolo[1,5-a]pyrimidin-3 |
|---|---|
| 规格或纯度 | Moligand™, ≥97% |
| 英文名称 | LarotrectinibFor |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | 神经营养受体酪氨酸激酶 1 抑制剂 |
| 产品介绍 |
Larotrectinib (Vitrakvi, LOXO-101, ARRY-470) 是一种具有ATP竞争性的、口服给药的 tropomyosin-related kinase (TRK) family receptors 的高度选择性抑制剂。 |
| 纯度 | ≥97% |
| ALogP | 1.7 |
|---|
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| PubChem SID | 504770672 |
|---|---|
| EC号 | 826-190-2 |
| 分子类型 | 小分子 |
| IIUPAC Name | (3S)-N-[5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-3-hydroxypyrrolidine-1-carboxamide |
| INCHI | 1S/C21H22F2N6O2/c22-13-3-4-16(23)15(10-13)18-2-1-7-28(18)19-6-9-29-20(26-19)17(11-24-29)25-21(31)27-8-5-14(30)12-27/h3-4,6,9-11,14,18,30H,1-2,5,7-8,12H2,(H,25,31)/t14-,18+/m0/s1 |
| InChi Key | NYNZQNWKBKUAII-KBXCAEBGSA-N |
| Smiles | C1CC(N(C1)C2=NC3=C(C=NN3C=C2)NC(=O)N4CCC(C4)O)C5=C(C=CC(=C5)F)F |
| Isomeric SMILES | C1C[C@@H](N(C1)C2=NC3=C(C=NN3C=C2)NC(=O)N4CC[C@@H](C4)O)C5=C(C=CC(=C5)F)F |
| 关联CAS | 1223403-58-4 |
| MeSH Entry Terms | (3S)-N-(5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide;ARRY-470;ARRY470;BAY-2757556;BAY2757556;larotrectinib;LOXO-101;LOXO101;N-(5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin- |
| 分子量 | 428.4 |
| Reaxy-Rn | 36507359 |
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=36507359&ln= |
| 分子量 | 428.400 g/mol |
|---|---|
| XLogP3 | 1.700 |
| 氢键供体数Hydrogen Bond Donor Count | 2 |
| 氢键受体数Hydrogen Bond Acceptor Count | 7 |
| 可旋转键计数Rotatable Bond Count | 3 |
| 精确质量Exact Mass | 428.177 Da |
| 单同位素质量Monoisotopic Mass | 428.177 Da |
| 拓扑极表面积Topological Polar Surface Area | 86.000 Ų |
| 重原子数Heavy Atom Count | 31 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 659.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 2 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 象形图 | GHS07 |
|---|---|
| 信号词 | 警告 |
| 危险声明 |
H302: 吞食有害 H317: 可能引起皮肤过敏反应 |
| 预防措施声明 |
P280: 戴防护手套/穿防护服/戴防护眼罩/戴防护面具。 |
| 1. Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo AS et al.. (2018) Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.. N Engl J Med, 378 (8): (731-739). [PMID:29466156] |
| 2. Scott LJ. (2019) Larotrectinib: First Global Approval.. Drugs, 79 (2): (201-206). [PMID:30635837] |